---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-202414"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:52:57.179106+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences names Natalie Holles CEO; CoMpass trial enrollment at 86 patients, nearing completion

## Summary
- New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.
- Founder Elisabet de los Pinos steps down as CEO and director; remains as consultant through October 2026.
- Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has 86 patients enrolled; >25 additional patients identified for screening.
- Company reiterates guidance: enrollment completion by mid-2026, topline data in H2 2027.
- ATM prospectus terminated; $6.7M gross proceeds raised from 1.06M shares sold.

## SEC filing metadata
- accession: 0001193125-26-202414
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/d117008d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-202414
- JSON: https://secwatch.observer/filing/0001193125-26-202414.json
- Plain text: https://secwatch.observer/filing/0001193125-26-202414.txt

## Key facts
- Executive change
  Elisabet de los Pinos departed as Chief Executive Officer and President at Aura Biosciences, Inc..
  - Action: departed
  - Role: Chief Executive Officer and President
  source text: Dr. Elisabet de los Pinos, the Company’s founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm
- Executive change
  Elisabet de los Pinos departed as Director at Aura Biosciences, Inc..
  - Action: departed
  - Role: Director
  source text: notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm
- Executive change
  Natalie Holles was appointed as Chief Executive Officer and President at Aura Biosciences, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: the Board of Directors (the “Board”) of Aura Biosciences, Inc. (the “Company”) appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.